



## News Release

### Suven Revenue up by 11.85%; PAT up by 15.38% for 9 months ended December' 2017

HYDERABAD, INDIA (30 Jan' 2018) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specialized in CRAMS for global life science companies and drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 31<sup>st</sup> December 2017. The Un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 30<sup>th</sup> Jan' 2018 at Hyderabad.

#### Financial Highlights for the 3<sup>rd</sup> Quarter ended December' 2017 (QoQ):

Growth in income	INR 1669 Mn vs 1120 Mn - up by 49.07%
Growth in PAT	INR 346 Mn vs 317 Mn - up by 8.99%
Growth in EBIDTA	INR 547 Mn vs 501 Mn - up by 9.08%

#### Financial Highlights for the 9 months' period ended December' 2017 (YoY):

Growth in income	INR 4256 Mn vs 3805 Mn - up by 11.85%
Growth in PAT	INR 958 Mn vs. 831 Mn - up by 15.38%
Growth in EBIDTA	INR 1557 Mn vs 1333 Mn - up by 16.79%

Suven's expenses on innovative R&D in Drug Discovery stood at INR 416 Mn (9.76% on revenue) for the 9 months' period ended Dec' 2017.

The Board has declared an Interim Dividend of Re. 1.50 per share (150% of face value of Rs. 1.00 each).

For more information on Suven please visit our Web site at <http://www.suven.com>

#### *Risk Statement:*

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*